泰莎基因治疗公司第四季度每股收益$(0.07) 优于预期$(0.08),销售额$202万低于预期$231万

财报速递2025-02-26
泰莎基因治疗公司(纳斯达克代码:TSHA)公布其季度每股亏损$(0.07),优于分析师一致预期的$(0.08),超出预期12.5%。与去年同期每股收益$0.92相比,本次为107.61%的下降。公司报告季度销售额为$202万,低于分析师预期的$231万,差距为12.43%。此外,与去年同期$360万的销售额相比,本季度销售额下降了43.90%。

以上内容来自Benzinga Earnings专栏,原文如下:

Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 107.61 percent decrease over earnings of $0.92 per share from the same period last year. The company reported quarterly sales of $2.02 million which missed the analyst consensus estimate of $2.31 million by 12.43 percent. This is a 43.90 percent decrease over sales of $3.60 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法